Ronald S Arellano is an expert in Medical imaging at Massachusetts General Hospital (United States). Ronald S Arellano has authored 241 publications, the most recent in 2026, and is an investigator in 2 clinical trials. SLR score: 645 (community average: 125). How the SLR is computed.

LeadR Profile

Ronald S Arellano Massachusetts General Hospital United States
645 ScienceLeadR Reputation 645
Network Map

Medical imaging

Subspecialties: Oncology - Urology - Gastroenterology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 2000 - 2026

Source: PubMed

Massachusetts General Hospital

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 241

Citations

Citations: 17 309 1st author: 16 Last author: 92 Unique author: 8


Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Interventional Radiology in the Management of Primary Liver Malignancies.
PMID 42512347 — cells, carcinoma, hepatocellular, neoplasms, liver, radiology, therapeutics, radiology, interventional, cholangiocarcinoma, intrahepatic cholangiocarcinoma
Cancers (Basel)20260
Portosystemic shunt creation in hepatic malignancies: Evaluation of risk for pulmonary metastasis development and progression.
PMID 42190470 — hypertension, neoplasms, magnetic resonance imaging, diagnostic imaging, portasystemic shunt, surgical, neoplasm metastasis, colorectal neoplasms
Clin Imaging20260
International multisociety Delphi consensus for liver tumour thermal ablation: margin assessment.
PMID 42061382 — neoplasms, liver
Lancet Oncol20260
International multisociety Delphi consensus for liver tumour thermal ablation: procedural and practice standards.
PMID 42061383 — safety, neoplasms, multiple chronic conditions, liver
Lancet Oncol20260
Percutaneous Endobiliary Radiofrequency Ablation (PERFA) for Unresectable Cholangiocarcinoma.
PMID 41832084 — laboratories, radiography, transaminases, radiology, drug-related side effects and adverse reactions, radiofrequency ablation, cholangiocarcinoma, bilirubin
Acad Radiol20260

Clinical Studies 2

Sources: ClinicalTrials, EU CTIS

Synthesis

By phase:

N/A 1
Phase 3 1

By status:

Completed 2

By type:

Interventional 2

By Monocentric/Multicentric:

monocentric 0
multicentric2to4 1
multicentric5to9 0
multicentricup10 1

Main Topics

LeadR Networks

Main global connection map